Evaluating Spike Antigenicity across Endemic Human Coronavirus Models using Flow Virometry
Jonathan BurnieiD, Caroline Ouano, Victor Luo, Christian K. O. DzuvoriD, Taiya Miller, Giancarlo Ospina, Nikhila S. TannetiiD, Li Hui Tan, Donald J. HameliD, Catherine Hammond, Hannah R. MatthewsiD, Lamount R. EvansoniD, Jeswin JosephiD, Sydney P. Moak, Phyllis J Kanki, Noam A. CoheniD, Susan Reich WeissiD, Kizzmekia S. CorbettiD
Abstract
While SARS-CoV-2 research has advanced rapidly since COVID-19, endemic human coronaviruses (HCoVs) remain comparatively understudied. Tools to phenotype spike (S), the primary antigenic target on coronaviruses, at the single-virion level could improve vaccine design by capturing variation in epitope availability and spike abundance. Here, we establish a calibrated flow virometry (FV) platform to quantify S antigenicity on native endemic (HCoV-229E, HCoV-OC43) and epidemic (SARS-CoV-2) coronaviruses directly in cell culture supernatants. FV revealed cell line-dependent differences in S antigenicity, including receptor-induced changes in epitope accessibility. Comparison of virion-associated S with recombinant stabilized S by ELISA and biolayer interferometry showed consistent binding for HCoV-OC43, MERS-CoV, and SARS-CoV-2, but differences for HCoV-229E, with FV resolving heterogeneity not captured by bulk assays. Finally, FV showed that HCoV-229E from patient-derived air-liquid interface cultures exhibited reduced antibody binding and distinct S antigenicity compared to cell line-derived virions. Together, these findings establish FV as a platform for single-virion analysis of HCoV antigenicity.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV
J. T. Ladner, S. N. Henson, … J. A. Altin·bioRxiv·Jul 27, 2020
- Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
S. Khan, R. Nakajima, … Prometheus Study Group·bioRxiv·Mar 24, 2020
- Expression and fusogenic activity of SARS CoV-2 Spike protein displayed in the HSV-1 Virion.
P. J. Desai·bioRxiv·Nov 28, 2023
- Use of the particle agglutination/particle agglutination-inhibition test for antigenic analysis of SARS-CoV-2
J. Kobayashi, S. Matsuyama, … K. Nakamura·bioRxiv·Sep 8, 2022
- High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19
S. H. Ko, E. Bayat Mokhtari, … E. A. Boritz·bioRxiv·Feb 21, 2021
- Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to virus escape
JOHN CLARKE, Luke M. Jones, … Raymond J. Owens·bioRxiv·Jan 8, 2026